Ascendis Pharma A/S Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH
COPENHAGEN, Denmark, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, announced today that it has …